GSK : Q1 2023 results infographic

GSK momentum continues, with strong start

to 2023, driving confidence in full-year ambitions

"We have made a strong start to 2023, with excellent performance across Vaccines, Specialty and General Medicines. We are now very focused on our upcoming launches, including for our potential RSV older adult vaccine, and on continuing to strengthen our pipeline - both organically with several positive late-stageread-outs already this year, and through targeted business development. Our continued momentum is also supporting our confidence in delivering our medium and long-term growth ambitions."

Emma Walmsley

Chief Executive Officer, GSK

			Vaccines
			£ 2.0bn
			+15%, +9%
Total sales	including and excluding COVID-19 solutions
Specialty Medicines
£7.0bn	£2.2bn
-8%, +10%	-33%, +13%
including and excluding COVID-19 solutions	including and excluding COVID-19 solutions
			General Medicines
			£2.7bn
			+9%
Adjusted Group		Total EPS			Adjusted EPS
operating margin
30.1%		36.8p			37.0p
Dividend	68	17
14p
vaccines and			pipeline assets
	specialty medicines in phase III /
	in pipeline			registration

Journalists/media see press release on www.gsk.com for full details on Q1 2023.

Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 44 to 46 of the press release.

Product group sales may not add to total sales due to rounding.

References to growth are at constant exchange rates (CER) unless stated otherwise.

Ahead Together